Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Gaucher Treatment Report
SAT-112 CLINICAL TRIAL OF VENGLUSTAT, A GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITOR, IS SUPPORTED BY PRECLINICAL AND PHASE 1 STUDY
venglustat - Drug Hunter
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Ziv Gan-Or on Twitter: "Despite being completely unclear whether glucosylceramide is relevant is PD, the plans for the trial continued as usual. Now, let's talk about some pre-clinical results, using mouse "PD
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD - ScienceDirect
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Sanofi halts venglustat clinical programme in kidney disease
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power
VENGLUSTAT - Emerging Insight and Market Forecast - 2030
Genes | Free Full-Text | The Genetics of Parkinson's Disease and Implications for Clinical Practice
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
PERIDOT – Patient ExpeRIence in fabry Disease On venglustaT | M.A.G.I.C Clinic
Novel targeted therapies for Parkinson's disease | Molecular Medicine | Full Text
Top 10 Fabry Disease Clinical Trials [2023 Studies] | Power
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Biomolecules | Free Full-Text | The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers
Cells | Free Full-Text | Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?